Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pan-cancer proteogenomics characterization of tumor immunity

Cell(2024)10.1016/j.cell.2024.01.027Source: DataRank Database

Pan-cancer proteogenomics characterization of tumor immunity is a research paper published in Cell (2024). On theSindex it has a DataRank of 1.7. It has been cited 91 times, with 81 citing works in its 1-hop citation network.

N/A

1.7DataRank · unranked

Scored on demand from live citation data

Open Access91 citations · 81 citing works in its network

Download PDF

Cite:

Linked data & code

dbgap nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (36 grants)OA: hybridTopics (14)IDs (PubMed, PMC)Annotations (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 39%Citation Network 61%

Base Score Contribution

0.678

From this paper's citation signal

Citation Network Contribution

1.1

From 50 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 81 citers.

A unified pan-cancer proteome atlas
Cancer Cell20253 citations10 referencesContributes 0.139
FAP+ gastric cancer mesenchymal stromal cells via paracrining INHBA and remodeling ECM promote tumor progression
International Immunopharmacology202412 citations47 referencesContributes 0.055
Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A)
European Journal of Cancer20246 citations36 referencesContributes 0.054
Proteomic and Phosphoproteomic analysis of thyroid papillary carcinoma: Identification of potential biomarkers for metastasis
Journal of Proteomics20246 citations37 referencesContributes 0.053
Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity
Molecular Cancer Therapeutics20258 citations45 referencesContributes 0.049

Authors (100)

Weiping Ma ORCID,Tomer M. Yaron ORCID,Francesca Pia Caruso ORCID,Nicole Tignor,Joshua M. Wang ORCID

Live enrichment

PubMed:38359819 PMC:PMC10988632

Howard Hughes Medical Institute

Grant: GT15758

Associazione Italiana per la Ricerca sul Cancro

Grant: 21846

National Cancer Institute

Grant: U24CA271114

National Cancer Institute

Grant: U01CA214116

National Cancer Institute

Grant: U24CA210955

National Cancer Institute

Grant: U24CA210993

National Cancer Institute

Grant: U24CA210985

National Cancer Institute

Grant: U24CA210954

National Cancer Institute

Grant: HHSN26100064

National Cancer Institute

Grant: U24CA210972

National Cancer Institute

Grant: U24CA210986

National Cancer Institute

Grant: U24CA210967

National Cancer Institute

Grant: U24CA270823

National Cancer Institute

Grant: U01CA214114

National Cancer Institute

Grant: U24CA210979

National Cancer Institute

Grant: HHSN261201500003I

National Cancer Institute

Grant: U01CA214125

US Department of Defense

Grant: DE-AC05-76RL01830

National Institutes of Health

Grant: F30CA271622

National Institutes of Health

Grant: P30ES017885

National Institutes of Health

Grant: U24CA224260

National Institutes of Health

Grant: 1F30CA265288

National Institutes of Health

Grant: U24CA264250

National Institutes of Health

Grant: T32GM136542

National Institutes of Health

Grant: R33CA263705

NCI NIH HHS

Grant: U54 CA263001

NCI NIH HHS

Grant: R35 CA197588

NCI NIH HHS

Grant: U24 CA271037

NCI NIH HHS

Grant: HHSN261201500003C

NCI NIH HHS

Grant: F30 CA265288

NIGMS NIH HHS

Grant: T32 GM146636

NCI NIH HHS

Grant: U24 CA271012

NCI NIH HHS

Grant: U24 CA271075

Battelle

Government of South Australia

U.S. Department of Health and Human Services

hybridLicense: cc-by-nc-nd

publisherhttp://www.cell.com/article/S0092867424000643/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867424000643?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867424000643?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10988632/pdf/nihms-1961879.pdf

repositoryhttps://www.osti.gov/biblio/2406480

MeSH Terms

HumansNeoplasmsCombined Modality TherapyProteomicsGenomicsTumor EscapeProteogenomics

Keywords

ImmunotherapyHistopathologykinase activitytumor immunityProteogenomicsImmune SubtypeMultiomic Deconvolution

Related Papers (10)

Hallmarks of Cancer: New Dimensions

N/A

1.4DataRank · unranked

Cancer Discovery(2022)

co-cited

10.1158/2159-8290.cd-21-1059

Hallmarks of Cancer: The Next Generation

N/A

1.7DataRank · unranked

Cell(2011)

co-citedsame journal

10.1016/j.cell.2011.02.013

Oncogenic Signaling Pathways in The Cancer Genome Atlas

N/A

1.2DataRank · unranked

Cell(2018)

co-citedsame journal

10.1016/j.cell.2018.03.035

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

N/A

7.3DataRank · unranked

Nature Biotechnology(2021)

co-cited

10.1038/s41587-021-01070-8

Evolution of delayed resistance to immunotherapy in a melanoma responder

N/A

3.6DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-021-01331-8

Methylscaper: an R/Shiny app for joint visualization of DNA methylation and nucleosome occupancy in single-molecule and single-cell data

N/A

0.446DataRank · unranked

Bioinformatics(2021)

co-cited

10.1093/bioinformatics/btab438

Signatures of copy number alterations in human cancer

N/A

7.8DataRank · unranked

Nature(2022)

co-cited

10.1038/s41586-022-04738-6

Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics

Top 10%

2.1DataRank

Cancer Research(2022)

co-cited

10.1158/0008-5472.can-21-2807

Integrated genomic analyses of ovarian carcinoma

N/A

1.3DataRank · unranked

Nature(2011)

co-cited

10.1038/nature10166

Robust enumeration of cell subsets from tissue expression profiles

N/A

1.4DataRank · unranked

Nature Methods(2015)

co-cited

10.1038/nmeth.3337

Pan-cancer proteogenomics characterization of tumor immunity

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (100)

Funding (36 grants)

Open Access

Topics

Annotations (Europe PMC)

Related Papers (10)